載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$7.73
−US$0.07 · -0.90%
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
前收盤價
US$7.73
−US$0.07 · -0.90%
盤中時間採用ET。市場資料可能有所延遲。
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
日內區間
目前US$7.73
52週區間
目前US$7.73
盤中時間採用ET。市場資料可能有所延遲。
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
日內區間
目前US$7.73
52週區間
目前US$7.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.97億 USD | 2.66億 USD | 2.02億 USD | 1.49億 USD | 9967.3萬 USD |
| 銷貨成本 | 1.04億 USD | 8397萬 USD | 6155.9萬 USD | 5884.2萬 USD | 4353.4萬 USD |
| 毛利 | 1.93億 USD | 1.82億 USD | 1.41億 USD | 8977.4萬 USD | 5613.9萬 USD |
| 研究與開發 | 957.6萬 USD | 917.2萬 USD | 1542.5萬 USD | 674.2萬 USD | 206.4萬 USD |
| 銷售、一般及管理費用 | 2.21億 USD | 1.98億 USD | 1.65億 USD | 1.42億 USD | 1.12億 USD |
| 營業費用 | 2.3億 USD | 2.17億 USD | 1.9億 USD | 1.55億 USD | 1.01億 USD |
| 利息收入 | 193.1萬 USD | 326.3萬 USD | 86萬 USD | 11.9萬 USD | 1000 USD |
| 利息支出 | 1969.4萬 USD | 1873.5萬 USD | 1383.2萬 USD | 909.7萬 USD | 139.6萬 USD |
| 折舊和攤銷 | 874.3萬 USD | 602萬 USD | 586.7萬 USD | 449.7萬 USD | 631.4萬 USD |
| 營業利益 | −3760萬 USD | −3441.1萬 USD | −4923.3萬 USD | −6533萬 USD | −4440.5萬 USD |
| 淨利 | −5164.1萬 USD | −5042萬 USD | −6168.5萬 USD | −7441.2萬 USD | −4681萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1404.4萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1226.03萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF696.76萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO419.61萬0.03%139.17億 USD0.24%US$356.78+0.94%
State Street SPDR S&P Pharmaceuticals ETFXPH331.28萬0.72%4.62億 USD0.35%US$64.65+1.60%
Vanguard Russell 2000 ETFVTWO310.39萬0.02%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA240.3萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares U.S. Pharmaceuticals ETFIHE159.32萬0.10%15.52億 USD0.37%US$100.09+1.24%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
